The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
An aldose reductase inhibitor reverses early diabetes‐induced changes in peripheral nerve function, metabolism, and antioxidative defense
Open accessAbstract
Aldose reductase inhibitors (ARIs) prevent peripheral nerve dysfunction and morphological abnormalities in diabetic animal models. However, some experimental intervention studies and clinical trials of ARIs on diabetic neuropathy appeared disappointing because of either 1) their inadequate design and, in particular, insufficient correction of the sorbitol pathway activity or 2) the inability to reverse established functional and metabolic deficits of diabetic neuropathy by AR inhibition in general. We evaluated whether diabetes‐induced changes in nerve function, metabolism, and antioxidative defense are corrected by the dose of ARI (sorbinil, 65 mg/kg/d in the diet), resulting in complete inhibition of increased sorbitol pathway activity. The groups included control rats and streptozotocin‐diabetic rats treated with/without ARI for 2 weeks after 4 weeks of untreated diabetes. ARI treatment corrected diabetes‐induced nerve functional changes; that is, decrease in endoneurial nutritive blood flow, motor and sensory nerve conduction velocities, and metabolic abnormalities (i.e., mitochondrial and cytosolic NAD + /NADH redox imbalances and energy deficiency). ARI restored nerve concentrations of two major non‐enzymatic antioxidants, reduced glutathione (GSH) and ascorbate, and completely arrested diabetes‐induced lipid peroxidation. In conclusion, treatment with adequate doses of ARIs (that is, doses that completely inhibit increased sorbitol pathway activity) is an effective approach for reversal of, at least, early diabetic neuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Williamson, D., Lund, P., & Krebs, H. (1967) · Biochemical Journal · doi:10.1042/bj1030514 · Cited by 1,871
Inoguchi, T., Li, P., Umeda, F., Yu, H. Y., Kakimoto, M., Imamura, M., Aoki, T., Etoh, T., Hashimoto, T., Naruse, M., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1939 · Cited by 1,577
The Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy
The Diabetes Control and Complications Trial Research Group. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-8-199504150-00001 · Cited by 602
The redox state of free nicotinamide-adenine dinucleotide phosphate in the cytoplasm of rat liver
Veech, R. L., Eggleston, L. V., & Krebs, H. A. (1969) · Biochemical Journal · doi:10.1042/bj1150609a · Cited by 563
Cited by
Oxidative Stress in the Pathogenesis of Diabetic Neuropathy
Vincent, A. M., Russell, J. W., Low, P., & Feldman, E. L. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0019 · Cited by 982
Diabetic neuropathy: Mechanisms to management
Edwards, J. L., Vincent, A. M., Cheng, H. T., & Feldman, E. L. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.05.005 · Cited by 790
Tomlinson, D. R., & Gardiner, N. J. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2294 · Cited by 564
Mechanism of diabetic neuropathy: Where are we now and where to go?
Yagihashi, S., Mizukami, H., & Sugimoto, K. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00070.x · Cited by 488
Glucose and reactive oxygen species
Bonnefont-Rousselot, D. (2002) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/00075197-200209000-00016 · Cited by 456
Metadata
- Authors
- Obrosova, I. G., Huysen, C. V., Fathallah, L., Cao, X., Greene, D. A., & Stevens, M. J.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2001-11-14
- Volume
- 16
- Issue
- 1
- Pages
- 1-26
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2099548046
- Cited by
- 212
- References
- 4
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.